idea-006 · desirability deck
Every slide states a condition that would have to be true, then reports where it stands using the candidate file's own claim and its own confidence tag. A deck never upgrades a tag, invents a number, or recommends anything, and there is no ask slide.
The chair: an adult with chronic bothersome tinnitus, the audiologist who would dispense the device, and the VA facility that might stock it.
How to read this: every slide is a condition, not a conclusion. A bracketed claim reference points into knowledge-base/candidates/idea-006.md — the number is the claim's position in its ## Claims list, the tag is copied from it and never adjusted here. A [no claim] marker means nothing in the file speaks to the condition at all. See docs/deck-spec.md.
What changed since the 2026-08-24 build — the load-bearing condition has been answered and replaced. That build asked whether the VA actually buys devices in this category. Company press materials now say the incumbent holds a VA Federal Supply Schedule contract effective 2024-06-17 [claim 40: unconfirmed]. The channel is open — and occupied. That moves the question this deck turns on; see slide 8. Rebuilt from the file, not patched.
Would have to be true: There would have to be a large, identifiable population of adults with chronic tinnitus of moderate or greater severity — and the VA population would have to be the densest, most reachable part of it.
Where it stands: The general population is now sourced: analysis of the 2007 National Health Interview Survey (75,764 respondents) found 9.6% 12-month tinnitus prevalence among US adults — an estimated 21.4 of 222.1 million — of whom 7.2% rated their tinnitus as a big or very big problem [claim 38: unconfirmed]. That second figure is the one that matters, because the severity qualifier is what the intended use turns on, and it narrows the population sharply [claim 10: unconfirmed]. The VA half is still unread: the claim that tinnitus is the most prevalent service-connected disability among US veterans remains unconfirmed [claim 8: unconfirmed], and the VA Annual Benefits Report — a free federal document outside this repo's connector set — has still not been opened.
What would settle it: The VA Annual Benefits Report itself. It is still the cheapest high-value read on the candidate and still nobody has opened it.
If it's false: The channel argument that distinguishes this from a generic follower disappears, and what remains is a second entrant into a category with a first mover [claim 16: unconfirmed].
Would have to be true: A patient would have to wear headphones and a transcutaneous stimulator on a fixed daily schedule, at home, for a full treatment cycle — for a treatment that reduces severity rather than curing anything.
Where it stands: Still unbacked for this device [claim 18: unconfirmed], and the class evidence that arrived since the last build is encouraging on exactly this point. A large randomized bimodal-neuromodulation settings trial reported an 83.8% treatment compliance rate, with 70.3% of participants indicating benefit [claim 32: unconfirmed]. In US real-world use, a 220-patient retrospective chart review of the incumbent device reported a 91.5% responder rate (95% CI 86.9%-94.5%) on the Tinnitus Handicap Inventory at approximately 12 weeks, among the 212 patients with outcome data [claim 33: unconfirmed]. Adherence to a daily home schedule looks like the least of this candidate's problems — for the incumbent's configuration.
What would settle it: The same figures read from full texts by a human, and specifically whether the compliance rate holds outside a trial's follow-up structure. Nothing in this repo can appraise them — every one of these is a literature scan.
If it's false: Treatment effect in the real world falls below the trial's, and the value proposition — already non-curative — narrows to nothing a patient will pay for twice.
Would have to be true: An audiologist would have to dispense it, a VA facility would have to stock it, and — for the differentiator to work — both would have to accept fitting done remotely.
Where it stands: The institutional half moved decisively and against the candidate. The VA schedule that covers this category is described [claim 30: unconfirmed], and the incumbent is reported to be on it since 2024-06-17, with eligibility extended to Department of Defense, Bureau of Prisons, Indian Health Services and Public Health Service beneficiaries [claim 40: unconfirmed] — a company press release, not a primary government source, and no connector here reads VA contracting. So the channel this candidate was "aimed first at" is demonstrably open and the first mover is standing in it. What remains unbacked is whether a second, cheaper device gets prescribed alongside it [claim 41: unconfirmed], whether VA dispensing is routine rather than case-by-case [claim 19: unconfirmed], and whether remote fitting is acceptable to anyone [claim 20: unconfirmed] — with the adjacent regulation's professional-fitting special control cutting against it [claim 5: verified].
What would settle it: The VA FSS contract listing read from the VA National Acquisition Center directly rather than from a press release; VA prosthetics purchasing rules; audiologist interviews on dispensing a second device and on remote fitting; the QVN classification's own special controls, read directly.
If it's false: The remote-fitting advantage is the thing being traded away, and the candidate becomes a price competitor with no other difference [claim 23: unconfirmed].
Would have to be true: Several thousand dollars out of pocket — or a VA dispense — would have to be worth a non-curative daily treatment.
Where it stands: The price is a Generator assumption [claim 11: unconfirmed] and no reimbursement code exists for the category [claim 7: unconfirmed], so the two buyers remain the VA and the self-payer. What the patient would be buying is better characterised than it was: an effect size of Cohen's d -0.87 to -0.92 on the Tinnitus Handicap Inventory in a 326-adult randomized double-blinded trial at 12 weeks, P<.001 [claim 31: unconfirmed], and a 91.5% real-world responder rate at a >7-point THI improvement threshold [claim 33: unconfirmed]. Both are the incumbent's configuration, not this device's.
What would settle it: VA prosthetics dispensing policy for tinnitus devices; the incumbent's published US price as the reference point.
If it's false: The private segment is a small self-pay market for a non-curative device, and the candidate is a price competitor in a channel the incumbent already occupies [claim 40: unconfirmed].
Would have to be true: A patient and an audiologist would have to accept evidence generated on the incumbent's electrode site as applying to this device's different one.
Where it stands: The comparative landscape is now well characterised and it favours the category strongly — which is the problem, because the category's evidence belongs to the incumbent. The guideline-recommended alternatives underperform: a Cochrane review of CBT (28 studies, n=2733) found a mean THI reduction of 5.65 points versus audiological care, below the review's own 7-point minimal clinically important difference [claim 35: unconfirmed], and a Cochrane review of sound therapy (8 studies, n=590) found no evidence that hearing aids, sound generators or combination devices are superior to waiting-list control, placebo or education-only [claim 36: unconfirmed]. The 2014 AAO-HNSF guideline recommends hearing aid evaluation and CBT, says clinicians "may offer" sound therapy, and contains no recommendation addressing bimodal neuromodulation at all [claim 39: unconfirmed]. Against that backdrop the bimodal class looks strong [claim 31: unconfirmed], [claim 33: unconfirmed] — and every one of those results was generated on tongue stimulation, not on this device's proposed site [claim 14: unconfirmed].
What would settle it: A single-arm study at the proposed electrode site. One nearer starting point now exists: a completed 100-participant randomized crossover trial of non-intraoral auditory-somatosensory bimodal stimulation, with results posted [claim 29: unconfirmed]. That is the closest published evidence to the transfer question and nobody has read it.
If it's false: The audiologist recommends the device with the trial behind it, which is the incumbent — and price alone has to overcome that [claim 22: unconfirmed].
Would have to be true: Two public documents and ten calls would have to establish whether the channel exists and whether anyone will dispense into it.
Where it stands: Half spent, and the answer reframed the question. The channel exists and the incumbent is on it [claim 40: unconfirmed], [claim 30: unconfirmed]. The VA Annual Benefits Report is still unread [claim 8: unconfirmed]. The calls have not been made, and the file is explicit that clinician preference has no connector — the follower-prescribing question is class 3, adoption-refused, and permanently unconfirmed absent primary research [claim 41: unconfirmed].
What would settle it: Read the VA Annual Benefits Report and the FSS listing, then call ten VA audiologists and ten private practices — now with a sharper question than the last build could ask: not "would you stock a bimodal device" but "you can already order Lenire; under what circumstances would you order a cheaper second one".
If it's false: The candidate is a follower product whose distinguishing feature — the channel — turns out to be occupied rather than absent, which is a harder problem than an unbuilt one.
Every condition above with nothing verified behind it.
adoption-refused, primary research only. The new
load-bearing condition.
The four verified claims are still all regulatory: the De Novo grant and its date [claim 1: verified], the classification it created [claim 2: verified], and two facts about the adjacent tinnitus-masker regulation [claim 5: verified], [claim 6: verified]. Thirteen new claims arrived since the last build, several of them strong clinical results, and none moved a tag — they are literature and press, which no connector here can verify. The class now has good evidence and the candidate still has none of its own.
If only one thing from this chair could be checked: whether VA audiologists would prescribe a cheaper follower bimodal device instead of, or alongside, the incumbent already available through the VA Federal Supply Schedule [claim 41: unconfirmed].
This replaces the previous build's condition because that one was answered. It asked whether the VA buys in this category at all; the answer appears to be yes, and the incumbent has held the contract since 2024-06-17, extended beyond VA to DoD, Bureau of Prisons, Indian Health Services and Public Health Service beneficiaries [claim 40: unconfirmed]. That is good news for the category and bad news for the thesis: the channel this candidate was aimed at is not an opening, it is a position someone else holds.
So the desirability question is no longer "is there a route to the patient" but "does a second, cheaper device get ordered when the first one is already on contract and has a published pivotal trial [claim 31: unconfirmed] and a 220-patient real-world series [claim 33: unconfirmed] behind it". The file classifies that as evidence class 3 — a stakeholder-future claim the adoption connector refuses — so it will never be resolved by tooling. It needs VA audiologists asked directly, and it is answerable this month.
Naming it is not a recommendation, a gate, or a kill.